OncoCyte Corporation found using ticker (OCX) now have 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 11 and 2 calculating the average target price we see 5.71. Given that the stocks previous close was at 5.35 this indicates there is a potential upside of 6.7%. The day 50 moving average is 3.59 and the 200 moving average now moves to 2.07. The market cap for the company is $379m. Company Website: http://www.oncocyte.com
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.